Business Information
The group's principal activity is to develop and commercialize proprietary cell-based research and diagnostic products with an initial focus on cancer. The group's products provides physicians and scientists with clinically meaningful information earlier than current diagnostic methods. Its products can identify, count and characterize the presence and quantity of a small number of tumor cells present in a blood sample. Major brand of the group is celltracks. Its products are based on an integrated system of instruments, reagents and other consumable and ancillary products used to isolate, label, count and analyze tumor cells in the blood, known as circulating tumor cells, or ctcs
|
|
Name |
Title
|
Email
|
| William Freytag | Chmn. | Available | | Carrie Mulherin | VP - Marketing | Available | | James Murphy | Sr. VP - Finance, Administration, CFO | Available | | James Wilcox | VP, Chief Counsel, Sec. | Available | | John Verrant | VP - Engineering | Available
|
|
|
Year |
Sales |
Net Income |
| 2006 | 8,697 | (23,998) | | 2005 | 4,647 | (26,908) | | 2004 | 1,565 | (27,933)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
